| abstract |
The present invention relates to fusion proteins comprising GDF15 variants with increased physiological activity and in vivo stability, and pharmaceutical compositions comprising the same. GDF15 variants or long-acting GDF15 fusion proteins according to the present invention are superior to conventional GDF15 variants in in vivo potency, binding affinity to the GDF15 receptor and weight loss. Therefore, the pharmaceutical composition comprising the GDF15 variant, long-acting GDF15 fusion protein or fusion protein dimer of the present invention as an active ingredient causes appetite suppression, and thus can be effectively used as a therapeutic agent for metabolic diseases or obesity. In addition, the pharmaceutical composition containing the GDF15 variant, long-acting GDF15 fusion protein or fusion protein dimer as an active ingredient can be used for combination therapy with chemical drugs and other therapeutic agents for metabolic diseases, etc., and can effectively For combination therapy with conventional therapeutic agents for metabolic disease or obesity. |